Axonis Therapeutics

Axonis Therapeutics is a private, clinical-stage biotech pioneering a novel approach to neurological disorders by potentiating the KCC2 transporter to restore functional inhibition in the brain. The company has advanced its lead candidate, AXN-027, into first-in-human trials in 2024, backed by a robust $115 million Series A financing round and a world-class team of experts. With a proprietary KCC2 discovery engine and a focus on high-need conditions like epilepsy and pain, Axonis is positioned to unlock a new therapeutic modality in a potential blockbuster drug space.

Proprietary KCC2 discovery engine utilizing customized assays to identify and optimize small molecule potentiators of the KCC2 transporter, aimed at restoring functional neuronal inhibition.

Direct competition targeting KCC2 potentiation is currently limited, making Axonis a pioneer. However, indirect competition is fierce, including numerous companies developing next-generation anti-seizure medications, pain therapeutics, and other modalities for neuronal hyperexcitability. Large pharma with established neurology portfolios represent potential future competitors or acquirers.